03 Mar 2005 - TopoTarget A/S has acquired G2M Cancer Drugs AG (G2M), the German anti-cancer therapeutics company. The move unites two companies with complementary strategies, products and research and creates a heavy weight Danish oncology company with subsidiaries in the UK and Germany. The new entity will be a leader in the field of histone deacetylase (HDAC) inhibitors, have a broad and rich development portfolio and the potential to reach sustainable profitability by 2007.
G2M's oncology portfolio includes two products based on the histone deacetylase (HDAC) inhibitor, G2M-777. BACECA® is currently in Phase II clinical evaluation and PEAC® is anticipated to enter Phase II later this year. Its third product, ZEMAB®, has just completed Phase I clinical trials.
 |
www.bionity.com/news/e/43907 |
|
 |
|
© Chemie.DE Information Service GmbH http://www.bionity.com/news/e/43907 |
Seydelstr. 28 · 10117 Berlin info@chemie.de · Tel: +49 (0)30 20 45 68 - 0 |